Skip to content
StockMarketAgent

UNH vs ELV: side-by-side analysis

Cross-read of UNH (UnitedHealth Group Incorporated) versus ELV (ELV): UNH screens modestly overvalued at $378 versus a fair-value midpoint of $340, while ELV appears in our peer table at a forward P/E of 12.8x and ROE of 12.1%. Our current rating for UNH is Reduce.

Where UNH and ELV sit on fair value

UNH's composite fair-value range is $230–$450 (midpoint $340), versus a current price of $378. ELV is one of UNH's closest sector neighbours and shows up directly in the peer table inside our full report, with a market-cap of $81.0B, P/E of 12.8x, EV/EBITDA of 8.9x, and an operating margin of 5.3%. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.

Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between UNH and ELV is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.

Where they actually differ

UNH is classified as a mature compounder stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. ELV, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 18.2× forward P/E with a PEG of 1.27 is not the same on UNH as it is on ELV unless they share the same growth profile, capital intensity, and moat half-life.

UNH's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against ELV should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.

Which one wins on each dimension

Valuation: UNH screens modestly overvalued versus our fair-value midpoint. The full report's peer table compares UNH and ELV directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for UNH is bound by the kill-scenarios list in Section 2; the equivalent for ELV would need its own report. We do not co-rate two companies on a single page.

Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether UNH or ELV is the better expression of the same theme.

Bottom line — UNH or ELV?

Our rating for UNH is Reduce with a 88/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes ELV. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.

For the full evidence on UNH, including the explicit peer multiples versus ELV and the rest of the comp set, see the canonical report at /stocks/unh/analysis. For ELV's standalone report, see /stocks/elv/analysis.

Frequently asked questions

UNH vs ELV: which is cheaper today?

UNH screens modestly overvalued at $378 versus a fair-value midpoint of $340 (range $230–$450). The peer table inside the full report compares UNH and ELV directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.

Is UNH a better buy than ELV?

Our current rating for UNH is Reduce; we do not co-rate ELV on this page — see ELV's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.

What archetype is UNH?

UnitedHealth Group Incorporated is classified as a mature compounder stock, which determines our deceleration curve, terminal multiple, and probability weights. ELV's own archetype is in its own report.

What is UNH's moat score versus ELV?

UNH's moat score is 9/10. The full moat section covers source, durability, and threat timeline; ELV's moat assessment is in its own standalone report.

Research for educational purposes. Not personalised investment advice. See the full UNH report for the canonical evidence.